The following options are acceptable choices for colorectal cancer screening in average-risk adults. Since each of the following tests has inherent characteristics related to accuracy, prevention potential, costs, and risks, individuals should have an opportunity to make an informed decision when choosing a screening test.
| Test |
Interval
(beginning
at age 50) |
Comment |
|
Colonoscopy |
Every 10 years |
Colonoscopy provides an opportunity to visualize, sample
and/or immediately remove significant lesions.
This test can find pre-cancer and cancer. |
|
Fecal Occult Blood Test (FOBT) |
Yearly |
The recommended take-home multiple sample method should
be used. All positive tests should be followed up with colonoscopy. |
|
Flexible sigmoidoscopy |
Every 5 years |
All positive tests should be followed up with colonoscopy.
This test can find pre-cancer and cancer. |
|
Fecal Occult Blood Test (FOBT) & Flexible
Sigmoidoscopy |
FOBT annually and flexible sigmoidoscopy every 5 years |
Flexible sigmoidoscopy together with FOBT is preferred compared
with FOBT or flexible sigmoidoscopy alone.
All positive tests
should be followed up with colonoscopy. |
|
Fecal Immunochemical Test (FIT) |
Yearly |
All positive tests should be followed up with colonoscopy. |
|
Virtual Colonoscopy (CT colonography) |
Every 5 years |
All positive tests will be followed up with colonoscopy.
This test can find pre-cancer and cancer. |
|
Stool DNA (sDNA) test |
Seek recommendation of a health care professional |
All positive tests should be followed up with colonoscopy |
| Risk Category |
Age to Begin |
Recommendation |
Comments |
|
INCREASED RISK |
|
People with a single, small (< 1 cm) adenoma |
3-6 years after the initial polypectomy |
Colonoscopy |
If the exam is normal, the patient can thereafter be screened
as per average risk guidelines. |
|
People with a large (1 cm +) adenoma, multiple adenomas,
or adenomas with high-grade dysplasia or villous change. |
Within 3 years after the initial polypectomy |
Colonoscopy |
If normal, repeat examination in 3 years; If normal then,
the patient can thereafter be screened as per average risk
guidelines. |
|
Personal history of curative-intent resection of colorectal
cancer |
Within 1 year after cancer resection |
Colonoscopy |
If normal, repeat examination in 3 years; If normal then,
repeat examination every 5 years. |
|
Either colorectal cancer or adenomatous polyps, in any first-degree
relative before age 60, or in two or more first-degree relatives
at any age (if not a hereditary syndrome). |
Age 40, or 10 years before the youngest case in the immediate
family |
Colonoscopy |
Every 5-10 years. Colorectal cancer in relatives more distant
than first-degree does not increase risk substantially above
the average risk group. |
| African Americans |
Age 45 |
Colonoscopy |
The guidelines were lowered due to earlier age
of diagnosis as well as higher death rate from colorectal cancer
in African Americans as compared with whites. The guidelines
also state the need for colonoscopy as "first-line"
screening procedure due to African Americans having more right-sided
colon cancers and polyps. |
|
HIGH RISK |
|
Family history of familial adenomatous polyposis (FAP) |
Puberty |
Early surveillance with endoscopy, and counseling to consider
genetic testing |
If the genetic test is positive, colectomy is indicated.
These patients are best referred to a center with experience
in the management of FAP. |
|
Family history of hereditary non-polyposis colon cancer (HNPCC) |
Age 21 |
Colonoscopy and counseling to consider genetic testing |
If the genetic test is positive or if the patient has not
had genetic testing, every 1-2 years until age 40, then annually.
These patients are best referred to a center with experience
in the management of HNPCC. |
|
Inflammatory bowel disease Chronic ulcerative colitis Crohn's
disease |
Cancer risk begins to be significant 8 years after the onset
of pancolitis, or 12-15 years after the onset of left-sided
colitis |
Colonoscopy with biopsies for dysplasia |
Every 1-2 years. These patients are best referred to a center
with experience in the surveillance and management of inflammatory
bowel disease. |